(Q46938486)

26 December 2017

title

Acute high-dose glycine attenuates mismatch negativity (MMN) in healthy human controls (English)

1 reference

26 December 2017

author name string

Sumie Leung

1

1 reference

26 December 2017

Rodney J Croft

2

1 reference

26 December 2017

Barry V O'Neill

3

1 reference

26 December 2017

Pradeep J Nathan

4

1 reference

26 December 2017

publication date

20 October 2007

1 reference

26 December 2017

number of pages

10

1 reference

inferred from page(s)

published in

Psychopharmacology

1 reference

26 December 2017

volume

196

1 reference

26 December 2017

issue

3

1 reference

26 December 2017

page(s)

451-460

1 reference

26 December 2017

Brain potential evidence for an auditory sensory memory deficit in schizophrenia.

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00213-007-0976-8

Recent advances in the phencyclidine model of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-007-0976-8

Amelioration of negative symptoms in schizophrenia by glycine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-007-0976-8

Glutamate receptor dysfunction and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-007-0976-8

Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-007-0976-8

Glycine prodrug facilitates memory retrieval in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-007-0976-8

Towards optimal recording and analysis of the mismatch negativity

21 January 2018

1 reference

12 December 2020

Glutamate and dopamine dysregulation in schizophrenia--a synthesis and selective review

1 reference

12 December 2020

Duration and frequency mismatch negativity in schizophrenia.

1 reference

12 December 2020

Stability of the mismatch negativity under different stimulus and attention conditions

1 reference

12 December 2020

Cerebral metabolic effects of intravenous glycine in healthy human subjects

1 reference

12 December 2020

Dissociation of the mismatch negativity and processing negativity attentional waveforms with nitrous oxide

1 reference

12 December 2020

Substantial shared genetic influences on schizophrenia and event-related potentials.

1 reference

12 December 2020

Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label, pilot study.

1 reference

12 December 2020

Glutamate receptors in the postmortem striatum of schizophrenic, suicide, and control brains

1 reference

12 December 2020

Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis

1 reference

12 December 2020

An open trial of glycine as an adjunct to neuroleptics in chronic treatment-refractory schizophrenics.

1 reference

12 December 2020

Separate representation of stimulus frequency, intensity, and duration in auditory sensory memory: an event-related potential and dipole-model analysis.

1 reference

12 December 2020

Separate Time Behaviors of the Temporal and Frontal Mismatch Negativity Sources

1 reference

12 December 2020

Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics.

1 reference

12 December 2020

Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders.

1 reference

12 December 2020

Glycine binding primes NMDA receptor internalization

1 reference

12 December 2020

Association between reduced duration mismatch negativity (MMN) and raised temporal discrimination thresholds in schizophrenia

1 reference

12 December 2020

Glycine transporter type 1 blockade changes NMDA receptor-mediated responses and LTP in hippocampal CA1 pyramidal cells by altering extracellular glycine levels

1 reference

12 December 2020

N-Methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives

1 reference

12 December 2020

The impact of glucose ingestion and gluco-regulatory control on cognitive performance: a comparison of younger and middle aged adults

1 reference

12 December 2020

Effects of olanzapine on auditory P300 and mismatch negativity (MMN) in schizophrenia spectrum disorders

1 reference

12 December 2020

Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications.

1 reference

12 December 2020

Clozapine and haloperidol modulate N-methyl-D-aspartate- and non-N-methyl-D-aspartate receptor-mediated neurotransmission in rat prefrontal cortical neurons in vitro.

1 reference

12 December 2020

Increases in strychnine-insensitive glycine binding sites in cerebral cortex of chronic schizophrenics: evidence for glutamate hypothesis

1 reference

12 December 2020

1 reference

12 December 2020

Early clinical pharmacological trials with a new anti-epileptic, milacemide, using pharmaco-EEG and psychometry.

1 reference

12 December 2020

Modulation of glycine receptor function: a novel approach for therapeutic intervention at inhibitory synapses?

1 reference

12 December 2020

Effects of NMDA receptor antagonist memantine on mismatch negativity

1 reference

12 December 2020

Impairment of early cortical processing in schizophrenia: an event-related potential confirmation study

1 reference

12 December 2020

Glutamate pharmacology and the treatment of schizophrenia: current status and future directions

1 reference

12 December 2020

Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment

1 reference

12 December 2020

Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics

1 reference

12 December 2020

Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia

1 reference

12 December 2020

Utility of a new procedure for diagnosing mental disorders in primary care. The PRIME-MD 1000 study

1 reference

12 December 2020

Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia.

1 reference

12 December 2020

Impairment in activation of a frontal attention-switch mechanism in schizophrenic patients

1 reference

12 December 2020

Adjunctive high-dose glycine in the treatment of schizophrenia

1 reference

12 December 2020

NMDA receptors are movin' in.

1 reference

12 December 2020

Placebo-controlled trial of glycine added to clozapine in schizophrenia

1 reference

12 December 2020

Age- and dose-dependent glucose-induced increases in memory and attention in schizophrenia.

1 reference

12 December 2020

Mismatch negativity deficits are associated with poor functioning in schizophrenia patients

1 reference

12 December 2020

NR2B-containing NMDA receptors are up-regulated in temporal cortex in schizophrenia

1 reference

12 December 2020

High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia

1 reference

12 December 2020

Mismatch negativity predicts psychotic experiences induced by NMDA receptor antagonist in healthy volunteers

1 reference

12 December 2020

The metabolic response to ingested glycine.

1 reference

12 December 2020

Beneficial effects of glycine (bioglycin) on memory and attention in young and middle-aged adults

1 reference

12 December 2020

Mismatch negativity (MMN): perspectives for application

1 reference

12 December 2020

Role of glucose in chewing gum-related facilitation of cognitive function

1 reference

12 December 2020

Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia

1 reference

12 December 2020

Cognitive effects of milacemide and methylphenidate in healthy young adults.

1 reference

12 December 2020

Striatal ionotropic glutamate receptor expression in schizophrenia, bipolar disorder, and major depressive disorder

1 reference

12 December 2020

Role of cortical N-methyl-D-aspartate receptors in auditory sensory memory and mismatch negativity generation: implications for schizophrenia

1 reference

12 December 2020

IV glycine and oral D-cycloserine effects on plasma and CSF amino acids in healthy humans

1 reference

12 December 2020

The emerging role of glutamate in the pathophysiology and treatment of schizophrenia

1 reference

12 December 2020

Subanesthetic doses of ketamine stimulate psychosis in schizophrenia

1 reference

12 December 2020

Mismatch negativity in schizophrenia: a meta-analysis

1 reference

12 December 2020

Chronic high-dose glycine nutrition: effects on rat brain cell morphology

1 reference

12 December 2020

Therapeutic trial with glycine in myoclonus

1 reference

12 December 2020

Mismatch negativity in schizophrenia: a family study

1 reference

12 December 2020

High glycine levels are associated with prepulse inhibition deficits in chronic schizophrenia patients

1 reference

12 December 2020

Impairment in frontal but not temporal components of mismatch negativity in schizophrenia

1 reference

12 December 2020

Mismatch negativity: an index of a preattentive processing deficit in schizophrenia

1 reference

12 December 2020

Modulation of striatal dopamine release by glycine transport inhibitors

1 reference

12 December 2020

Evidence for the different additivity of the temporal and frontal generators of mismatch negativity: a human auditory event-related potential study.

1 reference

12 December 2020

Glycine receptors: recent insights into their structural organization and functional diversity

1 reference

12 December 2020

10.1007/S00213-007-0976-8

Identifiers

DOI

1 reference

26 December 2017

1 reference

26 December 2017